| Summary: | Long-chain arylpiperazine scaffold is a versatile template to design central nervous system (CNS) drugs that target serotonin and dopamine receptors. Here we describe the synthesis and biological evaluation of ten new arylpiperazine derivatives designed to obtain an affinity profile at serotonin 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>7</sub> receptor, and dopamine D<sub>2</sub> receptor of prospective drugs to treat the core symptoms of autism spectrum disorder (ASD) or psychosis. Besides the structural features required for affinity at the target receptors, the new compounds incorporated structural fragments with antioxidant properties to counteract oxidative stress connected with ASD and psychosis. All the new compounds showed CNS MultiParameter Optimization score predictive of desirable ADMET properties and cross the blood–brain barrier. We identified compound <b>12a</b> that combines an affinity profile compatible with antipsychotic activity (5-HT<sub>1A</sub><i>K</i><sub>i</sub> = 41.5 nM, 5-HT<sub>2A</sub><i>K</i><sub>i</sub> = 315 nM, 5-HT<sub>7</sub><i>K</i><sub>i</sub> = 42.5 nM, D<sub>2</sub><i>K</i><sub>i</sub> = 300 nM), and compound <b>9b</b> that has an affinity profile consistent with studies in the context of ASD (5-HT<sub>1A</sub><i>K</i><sub>i</sub> = 23.9 nM, 5-HT<sub>2A</sub><i>K</i><sub>i</sub> = 39.4 nM, 5-HT<sub>7</sub><i>K</i><sub>i</sub> = 45.0 nM). Both compounds also had antioxidant properties. All compounds showed low in vitro metabolic stability, the only exception being compound <b>9b</b>, which might be suitable for studies in vivo.
|
|---|